Crescent Biopharma Inc (CBIO) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access CBIO Annual Balance Sheets →
This page allows investors to track Crescent Biopharma Inc's balance sheet development across multiple reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent171.59
Cash & Short-term Investments171.00
Accounts receivable0.00
Prepaid Expense And Other Assets Current7.41
Total Current Assets179.01
Equipment/Property/Plant Net0.88
Other Assets, Noncurrent2.88
Operating Lease Right Of Use Asset1.37
Total Assets182.76
Liabilities
Accounts Payable, Current AC0.00
Accrued Liabilities, Current7.41
Other Liabilities, Current11.13
Total Current Liabilities18.54
Total Long-term Debt0.00
Other liabilities, Noncurrent0.97
Accrued Expenses And Other Accrued Liabilities Current4.43
Warrant Liability Current-
Operating Lease Liability Noncurrent1.09
Total Liabilities19.50
Stockholders' Equity
Common Stock Value0.03
Additional Paid In Capital Common Stock379.16
Retained Earnings / Accumulated Deficit-219.93
Other Equity0.00
Common Stockholder's Equity159.26
Preferred Stockholder's Equity4.00
Total Stockholder's Equity163.26
Liabilities & Stockholder's Equity182.76
4 historic quarters locked

Sign in to unlock the full Crescent Biopharma Inc balance sheet history.

About Crescent Biopharma Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001628280-26-050869

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.